Abstract：
UNASSIGNED: Intravenous plasminogen replacement therapy for patients with plasminogen deficiency type 1 (hypoplasminogenemia) was recently approved for marketing in the US. In this case report, the authors describe a 33-year-old man with hypoplasminogenemia who developed nonhealing postsurgical wounds following trauma to his right hand despite receiving standard treatment for 4 months. The patient was enrolled in a compassionate-use protocol with intravenous plasminogen replacement therapy and experienced prompt resolution of surgical wounds. He was the first human patient to receive replacement therapy with plasminogen, human-tvmh in the US and first to demonstrate cutaneous wound healing in addition to resolution of ligneous lesions attributable to plasminogen deficiency type 1.
摘要：
■纤溶酶原替代治疗1型纤溶酶原缺乏症（低纤溶酶原血症）患者最近在美国批准上市。在这个案例报告中,作者描述了一名33岁的低纤溶酶原血症患者,尽管接受了4个月的标准治疗,但他的右手外伤后出现了无法愈合的术后伤口.该患者参加了静脉纤溶酶原替代疗法的体恤使用方案，并经历了手术伤口的迅速解决。他是第一个接受纤溶酶原替代疗法的人类患者，美国的human-tvmh，除了解决归因于纤溶酶原缺乏症1型的木质病变外，还首次证明皮肤伤口愈合。
